Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO 2024: Updates in Multiple Myeloma : Episode 2
Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.
EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024
Now Viewing
EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024
EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024
EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone
EP: 6.Future Directions in the Management of Multiple Myeloma
Video content above is prompted by the following:
- Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
Related Videos
Related Content
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Article
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
